<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069584</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01793-38</org_study_id>
    <nct_id>NCT05069584</nct_id>
  </id_info>
  <brief_title>TransPERineal Fusion Biopsy Versus transrECTal</brief_title>
  <acronym>PERFECT</acronym>
  <official_title>Efficacy and Safety of Prostate Biopsies by Transperineal Versus Transrectal Route: Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l'Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GCS Ramsay Santé pour l'Enseignement et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the efficacy and safety of 2 types of prostatic biopsies: transperineal biopsy&#xD;
      versus transrectal biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, comparative, randomized, controlled study in 2 parallel groups, open-label,&#xD;
      longitudinal, multicenter, aimed at demonstrating the non-inferiority of targeted&#xD;
      transperineal biopsies compared to targeted transrectal biopsies in terms of diagnostic&#xD;
      efficiency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the targeted biopsy in terms of detection of significant cancers.</measure>
    <time_frame>Day 21</time_frame>
    <description>Number of patients (%) diagnosed with International Society of Urological Pathology cancer grade ≥ 2 on targeted biopsies.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>transperineal biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The strategy evaluated is based on performing targeted and systematized prostate biopsies performed by the transperineal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>transrectal biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparison strategy is based on performing targeted and systematized prostate biopsies performed by the transrectal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>patient must have a biopsy for his prostate cancer</description>
    <arm_group_label>transperineal biopsy</arm_group_label>
    <arm_group_label>transrectal biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient having had a multiparametric prostatic MRI with the realization of 3 sequences&#xD;
             (T2, diffusion, perfusion) interpreted by a local referent radiologist in prostate MRI&#xD;
             or whose PI-RADS score is confirmed by rereading by a local referent radiologist in&#xD;
             prostate MRI in case prostate MRI performed outside the center;&#xD;
&#xD;
          -  Patient with at least one PI-RADS 4-5 lesion on MRI;&#xD;
&#xD;
          -  Patient eligible for prostate, transperineal and transrectal biopsies, targeted and&#xD;
             systematized;&#xD;
&#xD;
          -  Patient with negative pre-biopsy antibacteriological urine examination ;&#xD;
&#xD;
          -  Patient with prostate specific antigen (PSA) level ≤ 20 ng / mL;&#xD;
&#xD;
          -  Patient capable of understanding the information related to the study, answering&#xD;
             questionnaires in French, reading the instructions and having expressed their consent&#xD;
             to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has already had a prostate biopsy;&#xD;
&#xD;
          -  Patient with stage ≥ cT3a prostate cancer according to TNM classification version 8&#xD;
&#xD;
          -  Patient with negative MRI or whose lesions have a PI-RADS score &lt;4;&#xD;
&#xD;
          -  Patient with impassable rectal stenosis;&#xD;
&#xD;
          -  Patient with a dermatological disease preventing perineal access;&#xD;
&#xD;
          -  Patient with rectal amputation;&#xD;
&#xD;
          -  Patient presenting with a urinary tract infection;&#xD;
&#xD;
          -  Patient on anticoagulant treatment at an effective oral dose, not relayed;&#xD;
&#xD;
          -  Patient participating in another clinical trial, or in a period of exclusion from&#xD;
             another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guillaume PLOUSSARD</last_name>
    <phone>05 32 02 72 02</phone>
    <email>dr.gploussard@gmail.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

